دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
A US plan for HCV elimination
doi : 10.1016/S2468-1253(22)00396-X
Volume 8, Issue 1, January 2023, Page 1
New restrictions on JAK inhibitors in the EU
doi : 10.1016/S2468-1253(22)00397-1
Volume 8, Issue 1, January 2023, Page 1
NAFLD prevalence and severity in overweight and obese populations
*Sven M A Francque, Eveline Dirinck
doi : 10.1016/S2468-1253(22)00375-2
Volume 8, Issue 1, January 2023, Pages 2-3
Vedolizumab in paediatric IBD: a huge step forward but not there yet
Renz C W Klomberg, *Lissy de Ridder
doi : 10.1016/S2468-1253(22)00390-9
Volume 8, Issue 1, January 2023, Pages 3-5
Practicalities accessing precision medicine in biliary tract cancer
*Julien Edeline, Angela Lamarca
doi : 10.1016/S2468-1253(22)00352-1
Volume 8, Issue 1, January 2023, Pages 5-6
Has the COVID-19 pandemic changed endoscopy in the UK forever?
*Colin Rees, Ian Penman
doi : 10.1016/S2468-1253(22)00387-9
Volume 8, Issue 1, January 2023, Pages 6-8
Challenges in gastroenterology training in Australia
David S Prince, Georgina Cunningham, Jonathan O’Donnell, May Y W Wong
doi : 10.1016/S2468-1253(22)00316-8
Volume 8, Issue 1, January 2023, Pages 8-10
Robotic versus laparoscopic surgery for middle and low rectal cancer
Jeremy Meyer, George van der Schelling, Rogier Crolla
doi : 10.1016/S2468-1253(22)00314-4
Volume 8, Issue 1, January 2023, Page 11
Robotic versus laparoscopic surgery for middle and low rectal cancer
*Praveen S Kammar, Niharika R Garach
doi : 10.1016/S2468-1253(22)00379-X
Volume 8, Issue 1, January 2023, Pages 11-12
Robotic versus laparoscopic surgery for middle and low rectal cancer – Authors' reply
Jianmin Xu for the REAL Study Group
doi : 10.1016/S2468-1253(22)00391-0
Volume 8, Issue 1, January 2023, Pages 12-13
Cirrhosis and hepatocellular carcinoma at primary hospitals in sub-Saharan Africa: the opportunity of PEN-Plus
Neil Gupta, Santigie Sesay, Marta Patiño Rodriguez, Emily Wroe, Gene Bukhman
doi : 10.1016/S2468-1253(22)00336-3
Volume 8, Issue 1, January 2023, Pages 13-14
The Liver Meeting 2022
Hugh Thomas
doi : 10.1016/S2468-1253(22)00398-3
Volume 8, Issue 1, January 2023, Page 15
Research in Brief
Holly Baker
doi : 10.1016/S2468-1253(22)00394-6
Volume 8, Issue 1, January 2023, Page 16
Séverine Vermeire: advancing patient-centred research in IBD
Jennifer Thorley
doi : 10.1016/S2468-1253(22)00395-8
Volume 8, Issue 1, January 2023, Page 17
Flux Gourmet: a visual feast with a starved social mission
Joe Moody
doi : 10.1016/S2468-1253(22)00400-9
Volume 8, Issue 1, January 2023, Page 18
How to live when you could be dead
Georgia Bisbas
doi : 10.1016/S2468-1253(22)00399-5
Volume 8, Issue 1, January 2023, Page 19
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
Jingxuan Quek*, Kai En Chan*, Zhen Yu Wong*, Caitlyn Tan, Bryan Tan, Wen Hui Lim, Darren Jun Hao Tan, Ansel Shao Pin Tang, Phoebe Tay, Jieling Xiao, Jie Ning Yong, Rebecca Wenling Zeng, Nicholas W S Chew, Benjamin Nah, Anand Kulkarni, Mohammad Shadab Siddiqui, Yock Young Dan, Vincent Wai-Sun Wong, Arun J Sanyal, Mazen Noureddin, Mark Muthiah†, Cheng Han Ngâ€
doi : 10.1016/S2468-1253(22)00317-X
Volume 8, Issue 1, January 2023, Pages 20-30
Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study
Ohad Atia*, Zivia Shavit-Brunschwig*, Diane R Mould, Ronen Stein, Manar Matar, Marina Aloi, Oren Ledder, Gili Focht, Darja Urlep, Jeffrey Hyams, Efrat Broide, Batia Weiss, Jeremiah Levine, Richard K Russell, Dan Turner
doi : 10.1016/S2468-1253(22)00307-7
Volume 8, Issue 1, January 2023, Pages 31-42
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
William J Sandborn*, Julian Panés*, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F Valentine, David Laharie, Carolina BaÃa, Raja Atreya, Remo Panaccione, Grazyna Rydzewska, Humberto Aguilar, Séverine Vermeire, on behalf of the BERGAMOT Study Groupâ€
doi : 10.1016/S2468-1253(22)00303-X
Volume 8, Issue 1, January 2023, Pages 43-55
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
Choong-kun Lee, Hong Jae Chon, Jaekyung Cheon, Myung Ah Lee, Hyeon-Su Im, Joung-Soon Jang, Min Hwan Kim, Sejung Park, Beodeul Kang, Moonki Hong, Jin Won Kim, Hyung Soon Park, Myoung Joo Kang, Young Nyun Park, Hye Jin Choi
doi : 10.1016/S2468-1253(22)00335-1
Volume 8, Issue 1, January 2023, Pages 56-65
The intestinal barrier in disorders of the central nervous system
Carolina Pellegrini*, Matteo Fornai*, Vanessa D’Antongiovanni, Luca Antonioli, Nunzia Bernardini†, Pascal Derkinderenâ€
doi : 10.1016/S2468-1253(22)00241-2
Volume 8, Issue 1, January 2023, Pages 66-80
Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference
Joerg M Pollok*, Pascale Tinguely*, Marina Berenguer, Claus U Niemann, Dimitri A Raptis†, Michael Spiro†, on behalf of the ERAS4OLT.org collaborative‡
doi : 10.1016/S2468-1253(22)00268-0
Volume 8, Issue 1, January 2023, Pages 81-94
